TY - JOUR
T1 - Micrometastasis volume in lymph nodes determines disease recurrence rate of stage II colorectal cancer
T2 - A prospective multicenter trial
AU - Yamamoto, Hirofumi
AU - Murata, Kohei
AU - Fukunaga, Mutsumi
AU - Ohnishi, Tadashi
AU - Noura, Shingo
AU - Miyake, Yasuhiro
AU - Kato, Takeshi
AU - Ohtsuka, Masahisa
AU - Nakamura, Yurika
AU - Takemasa, Ichiro
AU - Mizushima, Tsunekazu
AU - Ikeda, Masataka
AU - Ohue, Masayuki
AU - Sekimoto, Mitsugu
AU - Nezu, Riichiro
AU - Matsuura, Nariaki
AU - Monden, Morito
AU - Doki, Yuichiro
AU - Mori, Masaki
N1 - Funding Information:
This work was supported by MEXT KAKENHI under grant number 10307028. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2016 AACR.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Purpose: We reported in a retrospective study that the presence of micrometastasis in lymph nodes, when assessed by carcinoembryonic antigen (CEA)-specific RT-PCR, is a significant prognostic factor in stage II colorectal cancer. The aim of this study was to clarify the clinical value of micrometastasis in a prospective multicenter trial. Experimental Design: From November 2001 to December 2005, a total of 419 colorectal cancer cases were preoperatively registered at a central data center. Of them, 315 node-negative stage II colorectal cancer cases were enrolled. After RNA quality check, 304 colorectal cancer cases were analyzed for CEA mRNA in lymph nodes by both conventional RT-PCR (a band method) and quantitative RT-PCR. Long-term prognosis of the patients was determined by each method. Results: A positive band for CEA mRNA was detected in 73 (24.0%) of 304 patients. Postoperative adjuvant chemotherapy was applied in 31 CEA band-positive cases with an oral 5-fluorouracil derivative HCFU (1-hexylcarbamoyl-5-fluorouracil) for 1 year, whereas chemotherapy was not administered to CEA band-negative group. Multivariate Cox regression analyses revealed that a high micrometastasis volume (high MMV, n = 95) was an independent poor prognostic factor for 5-year disease-free survival (DFS; P = 0.001) and 5-year overall survival (OS; P = 0.016). Conclusions: This prospective clinical trial demonstrates that micrometastasis volume is a useful marker in identifying patients who are at high or low risk for recurrence of stage II colorectal cancer.
AB - Purpose: We reported in a retrospective study that the presence of micrometastasis in lymph nodes, when assessed by carcinoembryonic antigen (CEA)-specific RT-PCR, is a significant prognostic factor in stage II colorectal cancer. The aim of this study was to clarify the clinical value of micrometastasis in a prospective multicenter trial. Experimental Design: From November 2001 to December 2005, a total of 419 colorectal cancer cases were preoperatively registered at a central data center. Of them, 315 node-negative stage II colorectal cancer cases were enrolled. After RNA quality check, 304 colorectal cancer cases were analyzed for CEA mRNA in lymph nodes by both conventional RT-PCR (a band method) and quantitative RT-PCR. Long-term prognosis of the patients was determined by each method. Results: A positive band for CEA mRNA was detected in 73 (24.0%) of 304 patients. Postoperative adjuvant chemotherapy was applied in 31 CEA band-positive cases with an oral 5-fluorouracil derivative HCFU (1-hexylcarbamoyl-5-fluorouracil) for 1 year, whereas chemotherapy was not administered to CEA band-negative group. Multivariate Cox regression analyses revealed that a high micrometastasis volume (high MMV, n = 95) was an independent poor prognostic factor for 5-year disease-free survival (DFS; P = 0.001) and 5-year overall survival (OS; P = 0.016). Conclusions: This prospective clinical trial demonstrates that micrometastasis volume is a useful marker in identifying patients who are at high or low risk for recurrence of stage II colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=84977111897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977111897&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-2199
DO - 10.1158/1078-0432.CCR-15-2199
M3 - Article
C2 - 26831719
AN - SCOPUS:84977111897
VL - 22
SP - 3201
EP - 3208
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 13
ER -
